Isomorphic Labs, Secures Strategic Research Agreement with Eli Lilly and Novartis AG

Isomorphic Labs, a branch of Alphabet Inc., has formalized a strategy-based research contract with Eli Lilly and Novartis AG.  

As per the alliance with Eli Lilly, Isomorphic Labs is set to obtain an initial payment of $45m for joint research endeavors focused on small-molecule therapeutics addressing various targets, as indicated in the firm’s announcement.  

The firm has the potential to earn up to $1.7bn in results-driven targets, not including the initial payment and any further royalty fees.   

The leading executive of biomedical research at Novartis, Fiona Marshall, commented, “This collaboration harnesses our companies’ unique strengths, from AI and data science to medicinal chemistry and deep disease area expertise, to realize new possibilities in AI-driven drug discovery.”  

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.